SCHEMBL3211571

SCHEMBL3211571

COC(=O)N(C)NC(=O)c1cc(Br)cc(Br)c1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 3/20 0.33
NCEH1 Q6PIU2 2/20 0.33
CYP1A2 P05177 2/20 0.33
PTGS1 P23219 2/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 2/20 0.33
KMT2A Q03164 2/20 0.33
EGFR P00533 1/20 0.33
LMNA P02545 1/20 0.33
ERBB2 P04626 1/20 0.33
LCK P06239 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTT P42858 1/20 0.33
MAPK14 Q16539 1/20 0.33
AKR1C4 P17516 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221115 0.82 CYP1A2 (0.36) HSD17B10KDM4EALDH1A1CYP1A2PTGS1
SCHEMBL13300851 0.78 HSD17B10 (0.40) HSD17B10KDM4EALDH1A1NCEH1CYP1A2
SCHEMBL3214512 0.77 HSD17B10 (0.39) HSD17B10KDM4EALDH1A1CYP1A2PTGS1
SCHEMBL1119372 0.75 KDM4E (0.49) HSD17B10KDM4EALDH1A1MAPTAKR1C4
SCHEMBL27953419 0.75 CREBBP (0.41) HSD17B10KDM4EALDH1A1CYP1A2PTGS1
SCHEMBL29562450 0.75 KDM4E (0.49) HSD17B10KDM4EALDH1A1MAPTAKR1C4
SCHEMBL640590 0.75 ALDH1A1 (0.44) HSD17B10ALDH1A1CYP1A2PTGS1MEN1
SCHEMBL11983650 0.73 HSD17B10 (0.38) HSD17B10KDM4EALDH1A1CYP1A2PTGS1
SCHEMBL29242839 0.73 ALDH1A1 (0.43) HSD17B10KDM4EALDH1A1CYP1A2PTGS1
SCHEMBL639245 0.72 AKR1C4 (0.38) HSD17B10KDM4EALDH1A1CYP1A2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2143721-B1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL CO (JP) 2012-08-15 EP disclosed
US-20100048640-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2143721-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048640-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME CYC1, L3MBTL1, CBR3 HSD17B10 2530/4885KDM4E 2227/4885ALDH1A1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.